| Title |
Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, June 2014
|
| DOI | 10.1007/s10549-014-3026-3 |
| Pubmed ID | |
| Authors |
Jacek Gronwald, Andre Robidoux, Charmaine Kim-Sing, Nadine Tung, Henry T. Lynch, William D. Foulkes, Siranoush Manoukian, Peter Ainsworth, Susan L. Neuhausen, Rochelle Demsky, Andrea Eisen, Christian F. Singer, Howard Saal, Leigha Senter, Charis Eng, Jeffrey Weitzel, Pal Moller, Dawna M. Gilchrist, Olufunmilayo Olopade, Ophira Ginsburg, Ping Sun, Tomasz Huzarski, Jan Lubinski, Steven A. Narod, The Hereditary Breast Cancer Clinical Study Group |
| Abstract |
Women with a mutation in BRCA1 or BRCA2 face a lifetime risk of breast cancer of approximately 80 %. Tamoxifen treatment of the first cancer has been associated with a reduction in the risk of a subsequent contralateral cancer. We studied 1,504 women with a known BRCA1 or BRCA2 mutation, 411 women with bilateral breast cancer (cases) and 1,093 women with unilateral breast cancer (controls) in a matched case-control study. Control women were of similar age and had a similar age of diagnosis of first breast cancer as the cases. For each woman who used tamoxifen, the starting and stopping dates were abstracted and the duration of tamoxifen use was calculated. Three hundred and thirty-one women had used tamoxifen (22 %); of these 84 (25 %) had completed four or more years of tamoxifen, the remainder stopped prematurely or were current users. For women with up to 1 year of tamoxifen use, the odds ratio for contralateral breast cancer was 0.37 (95 % CI 0.20-0.69; p = 0.001) compared to women with no tamoxifen use. Among women with 1-4 years of tamoxifen use the odds ratio was 0.53 (95 % CI 0.32-0.87; p = 0.01). Among women with four or more years of tamoxifen use the odds ratio was 0.83 (95 % CI 0.44-1.55; p = 0.55). Short-term use of tamoxifen for chemoprevention in BRCA1 and BRCA2 mutation carriers may be as effective as a conventional 5-year course of treatment. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 44% |
| United Kingdom | 2 | 22% |
| Unknown | 3 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 6 | 67% |
| Scientists | 1 | 11% |
| Practitioners (doctors, other healthcare professionals) | 1 | 11% |
| Science communicators (journalists, bloggers, editors) | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 2% |
| Spain | 1 | 2% |
| Russia | 1 | 2% |
| Unknown | 61 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 17% |
| Professor | 7 | 11% |
| Student > Bachelor | 7 | 11% |
| Student > Doctoral Student | 5 | 8% |
| Other | 5 | 8% |
| Other | 12 | 19% |
| Unknown | 17 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 33% |
| Biochemistry, Genetics and Molecular Biology | 8 | 13% |
| Agricultural and Biological Sciences | 7 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Nursing and Health Professions | 2 | 3% |
| Other | 4 | 6% |
| Unknown | 19 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 March 2017.
All research outputs
#3,651,974
of 22,757,541 outputs
Outputs from Breast Cancer Research and Treatment
#649
of 4,652 outputs
Outputs of similar age
#36,646
of 228,424 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#9
of 51 outputs
Altmetric has tracked 22,757,541 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,652 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,424 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.